SecBot SecBot
Insider Cluster (3 insiders) ·Filed Jun 5, 2026

XERS

Xeris Biopharma Holdings, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $192K total
Actionable Insight • Neutral

The insider selling is trivial in size and likely tied to equity grant vesting, not a negative signal. Monitor for any upcoming earnings or pipeline catalysts that could move the stock, but this cluster alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.24
T+0 close · Jun 5, 2026 · via day close
Latest settled
+35.10%
T+60 · $8.43
Vs SPY
+32.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 8 $6.24entry
  2. T+1 · 5mo ago +4.17%α +4.46% · $6.50
  3. T+5 · 5mo ago +10.26%α +8.14% · $6.88
  4. T+20 · 4mo ago +34.13%α +32.50% · $8.37
  5. T+60 · 3mo ago +35.10%α +32.04% · $8.43

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

A cluster of insider selling at Xeris Biopharma, totaling $192K in open-market sales by two directors and an officer, occurred alongside large non-cash equity grants to four directors. The sales represent ~0.017% of the $1.1B market cap, a trivial amount, and are likely liquidity-driven following the vesting of restricted stock grants. No material bearish signal is present.

Key Financial Metrics

Direction
selling
Total Value
$192.0K
Insiders
3

Key Facts

  • Three insiders sold a total of $192K in open-market sales: Director John Johnson ($91K), Director Dawn Halkuff ($122K), and Officer Beth Hecht ($101K).
  • Four directors received non-cash equity grants totaling ~$609K in value (at $6.15/share) and additional zero-value grants.
  • Total open-market sales represent ~0.017% of the $1.1B market cap, well below the 0.1% threshold for materiality.
  • Sales occurred on the same day as large equity grants, suggesting a routine pattern of selling to cover tax obligations or diversify after vesting.

Financial Impact

Open-market sales of $192K, or ~0.017% of market cap, are immaterial relative to company size.

insider holdingsdilution

Risk Factors

  • No material risk identified from this insider activity; the cluster is routine and non-informative.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-XERS-1780697908162

US Market Status

Market Closed · Opens in 5h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026